Overview

A 90-gene gastric cancer panel that spans targeted-therapy genes, chemotherapy-response markers, and MSI/MMR status is a multi-dimensional test whose reliability depends on rigorous quality systems. For distributors and laboratories bringing such a panel to market, compliance is not paperwork but the foundation of clinical trust. This article outlines the quality and regulatory framework that should surround a panel of this scope.

Validating a Multi-Marker Assay

Because the panel reports three distinct marker types, validation must address each. Targeted and chemotherapy gene performance is confirmed through sensitivity, specificity, and limit-of-detection studies on representative samples. MSI/MMR assessment requires its own validation, including comparison against an accepted reference method, since calling instability or repair deficiency incorrectly has direct therapeutic consequences.

Quality Management Systems

Clinical use generally requires operation under an accredited quality system with documented procedures, personnel competency records, and proficiency testing. Reagents and instruments should be under change control so that updates do not silently alter performance. For cross-border distribution, confirm which accreditation and in-country approvals apply, because a panel valid in one region may need separate authorization elsewhere.

Transparent Reporting

Reports should disclose the assay version, the method used for each marker, and known limitations such as low tumor content or ambiguous MSI calls. Clear communication of what the chemotherapy-response portion can and cannot predict protects against over-interpretation. A well-structured report, backed by validated methods, is the final link that makes the multi-marker data clinically usable.

Supplier due diligence rounds out the framework. Before onboarding a 90-gene gastric panel, buyers should request evidence of validation studies, accreditation scope that covers each marker type, and clarity on which entity owns the report and the underlying data. A supplier that can demonstrate these controls reduces downstream compliance risk and makes it easier to defend the test's use if questioned by a regulator, payer, or accreditation surveyor during review.

FAQ

Q: How is MSI/MMR validated differently from genes? A: MSI/MMR needs its own validation, including comparison to a reference method, because miscalling it affects immunotherapy decisions.

Q: What quality system is expected? A: Accredited systems such as CAP/CLIA or ISO 15189 equivalents, with documented procedures and proficiency testing.

Q: Does the panel need per-region approval? A: Often yes. Distributors should confirm the required in-country authorization, as validity in one market does not guarantee it in another.

Q: What should the report disclose? A: Assay version, method per marker, and limitations such as low tumor content or ambiguous MSI results. Clinics should also receive guidance on result stability and the conditions under which a repeat test would be appropriate, so that the multi-marker report remains usable across the full course of treatment.